Trial Outcomes & Findings for N-Acetyl-L-Leucine for GM2 Gangliosidosis (Tay-Sachs and Sandhoff Disease) (NCT NCT03759665)
NCT ID: NCT03759665
Last Updated: 2024-03-12
Results Overview
The Clinical Impression of Change in Severity assessment will instruct the blinded rater to consider: compared to the first video, how has the severity of their performance on the 9 Hole Peg Test of the Dominant Hand (9HPT-D) or 8 Meter Walk Test (8MWT) changed (improved or worsened) in 6-weeks as observed in the second video? The Clinical Impression of Change in Severity is evaluated on a 7 point Likert scale (+3=significantly improved to -3= significantly worse). Change values were calculated for each period, i.e. treatment with IB1001 (comparing the end of treatment (Visit 4) with baseline (Visit 2)) and post-treatment washout (comparing the end of washout (Visit 6) with the end of treatment (Visit 4)). Then, the mean change obtained in the post-treatment period was subtracted from the mean change obtained for the treatment with IB1001 period, with a positive value indicating an improvement in the treatment period compared to the post-treatment washout period.
COMPLETED
PHASE2
30 participants
(CI-CS comparing Baseline [Day 1] with IB1001 versus the end of 6-weeks treatment with IB1001 [approximately Day 42]) MINUS (CI-CS comparing the end of 6-weeks treatment with IB1001 [approximately Day 42] versus end of 6-weeks post-treatment washout);
2024-03-12
Participant Flow
Participant milestones
| Measure |
Parent Study
6-weeks treatment with IB1001 administered orally. Patients ≥13 years old received a total daily dose of 4 g/day (administered as 3 doses per day).
Patients 6-12 years old received weight-tiered doses:
* Patients aged 6-12 years weighing 15 to \<25 kg took 2g per day: 1 g in the morning and 1 g in the evening.
* Patients aged 6-12 years weighing 25 to \<35 kg took take 3g per day: 1 g in the morning, 1g in the afternoon, and 1 g in the evening.
* Patients aged 6-12 years weighing ≥35 kg took 4 g per day: 2 g in the morning, 1g in the afternoon and 1 g in the evening (as per adults).
IB1001: IB1001 (N-Acetyl-L-Leucine) is a modified amino-acid ester that is orally administered.
After the 6-week treatment period, patients entered a 6-week post-treatment washout period.
|
|---|---|
|
Treatment With IB1001
STARTED
|
30
|
|
Treatment With IB1001
COMPLETED
|
27
|
|
Treatment With IB1001
NOT COMPLETED
|
3
|
|
Post-Treatment Washout
STARTED
|
27
|
|
Post-Treatment Washout
COMPLETED
|
27
|
|
Post-Treatment Washout
NOT COMPLETED
|
0
|
Reasons for withdrawal
Withdrawal data not reported
Baseline Characteristics
N-Acetyl-L-Leucine for GM2 Gangliosidosis (Tay-Sachs and Sandhoff Disease)
Baseline characteristics by cohort
| Measure |
Parent Study
n=30 Participants
All patients were first dosed with IB1001.Therefore, the baseline characteristics of patients dosed in the first IB1001treatment period in the parent study constitute the baseline characteristics for the entire study.
|
|---|---|
|
Age, Continuous
|
27 years
STANDARD_DEVIATION 15.2 • n=93 Participants
|
|
Sex: Female, Male
Female
|
19 Participants
n=93 Participants
|
|
Sex: Female, Male
Male
|
11 Participants
n=93 Participants
|
|
Ethnicity (NIH/OMB)
Hispanic or Latino
|
0 Participants
n=93 Participants
|
|
Ethnicity (NIH/OMB)
Not Hispanic or Latino
|
22 Participants
n=93 Participants
|
|
Ethnicity (NIH/OMB)
Unknown or Not Reported
|
8 Participants
n=93 Participants
|
|
Region of Enrollment
United States
|
10 participants
n=93 Participants
|
|
Region of Enrollment
United Kingdom
|
1 participants
n=93 Participants
|
|
Region of Enrollment
Germany
|
18 participants
n=93 Participants
|
|
Region of Enrollment
Spain
|
1 participants
n=93 Participants
|
|
Tay-Sachs vs. Sandhoff Patients
Tay-Sachs
|
27 participants
n=93 Participants
|
|
Tay-Sachs vs. Sandhoff Patients
Sandhoff
|
3 participants
n=93 Participants
|
PRIMARY outcome
Timeframe: (CI-CS comparing Baseline [Day 1] with IB1001 versus the end of 6-weeks treatment with IB1001 [approximately Day 42]) MINUS (CI-CS comparing the end of 6-weeks treatment with IB1001 [approximately Day 42] versus end of 6-weeks post-treatment washout);Population: Modified Intention to Treat (mITT) Analysis Set is defined as all patients who receive at least one dose of the study drug and with one video recording during the baseline period (Visit 1 or 2, or both) and treatment period (Visit 3 or Visit 4, or both).
The Clinical Impression of Change in Severity assessment will instruct the blinded rater to consider: compared to the first video, how has the severity of their performance on the 9 Hole Peg Test of the Dominant Hand (9HPT-D) or 8 Meter Walk Test (8MWT) changed (improved or worsened) in 6-weeks as observed in the second video? The Clinical Impression of Change in Severity is evaluated on a 7 point Likert scale (+3=significantly improved to -3= significantly worse). Change values were calculated for each period, i.e. treatment with IB1001 (comparing the end of treatment (Visit 4) with baseline (Visit 2)) and post-treatment washout (comparing the end of washout (Visit 6) with the end of treatment (Visit 4)). Then, the mean change obtained in the post-treatment period was subtracted from the mean change obtained for the treatment with IB1001 period, with a positive value indicating an improvement in the treatment period compared to the post-treatment washout period.
Outcome measures
| Measure |
Parent Study
n=29 Participants
6-weeks treatment with IB1001administered orally. Patients ≥13 years old received a total daily dose of 4 g/day (administered as 3 doses per day).
Patients 6-12 years old received weight-tiered doses:
* Patients aged 6-12 years weighing 15 to \<25 kg took 2g per day: 1 g in the morning and 1 g in the evening.
* Patients aged 6-12 years weighing 25 to \<35 kg took 3g per day: 1 g in the morning, 1g in the afternoon, and 1 g in the evening.
* Patients aged 6-12 years weighing ≥35 kg took 4 g per day: 2 g in the morning, 1g in the afternoon and 1 g in the evening (as per adults)
IB1001: IB1001 (N-Acetyl-L-Leucine) is a modified amino-acid ester that is orally administered.
After the 6-week treatment period,patients entered a 6-week post-treatment washout period.
|
|---|---|
|
Clinical Impression of Change in Severity (CI-CS) [Fields et al 2021]
|
0.71 score on a scale
Standard Deviation 2.09
|
SECONDARY outcome
Timeframe: Baseline to end of treatment with IB1001 (Parent Study 6-weeks treatment); End of treatment with IB1001 to the end of post 6-week treatment washout.Population: Modified Intention to Treat (mITT) Analysis Set is defined as all patients who receive at least one dose of the study drug and with one video recording during the baseline period (Visit 1 or 2, or both) and treatment period (Visit 3 or Visit 4, or both). The overall mITT comprised 29 participants. Of these, 29 participants had values for the CI-CS analysis in the Treatment with IB1001 period and 27 participants in the Post-Treatment washout period.
The Clinical Impression of Change in Severity assessment will instruct the blinded rater to consider: compared to the first video, how has the severity of their performance on the 9 Hole Peg Test of the Dominant Hand (9HPT-D) or 8 Meter Walk Test (8MWT) changed (improved or worsened) in 6-weeks as observed in the second video? The Clinical Impression of Change in Severity is evaluated on a 7 point Likert scale (+3=significantly improved to -3= significantly worse). Change values were calculated for each period, i.e. treatment with IB1001 (comparing the end of treatment (Visit 4) with baseline (Visit 2)) and post-treatment washout (comparing the end of washout (Visit 6) with the end of treatment (Visit 4)).
Outcome measures
| Measure |
Parent Study
n=29 Participants
6-weeks treatment with IB1001administered orally. Patients ≥13 years old received a total daily dose of 4 g/day (administered as 3 doses per day).
Patients 6-12 years old received weight-tiered doses:
* Patients aged 6-12 years weighing 15 to \<25 kg took 2g per day: 1 g in the morning and 1 g in the evening.
* Patients aged 6-12 years weighing 25 to \<35 kg took 3g per day: 1 g in the morning, 1g in the afternoon, and 1 g in the evening.
* Patients aged 6-12 years weighing ≥35 kg took 4 g per day: 2 g in the morning, 1g in the afternoon and 1 g in the evening (as per adults)
IB1001: IB1001 (N-Acetyl-L-Leucine) is a modified amino-acid ester that is orally administered.
After the 6-week treatment period,patients entered a 6-week post-treatment washout period.
|
|---|---|
|
Key Secondary Endpoint: Individual Components of the CI-CS
Treatment with IB1001
|
0.34 score on a scale
Standard Deviation 1.59
|
|
Key Secondary Endpoint: Individual Components of the CI-CS
Post-TreatmentWashout
|
-0.36 score on a scale
Standard Deviation 1.33
|
SECONDARY outcome
Timeframe: (CI-S comparing baseline period [average for Visit 1 and 2] and end of treatment period [average for Visit 3 and 4]) minus (change in CI-S between end of treatment period [average for Visit 3 and 4] and end of washout period [average for Visit 5 and 6]).Population: Modified Intention to Treat (mITT) Analysis Set is defined as all patients who receive at least one dose of the study drug and with one video recording during the baseline period (Visit 1 or 2, or both) and treatment period (Visit 3 or Visit 4, or both).
The Change in Severity assessment will instruct the blinded rater to consider the severity of the patient at each visit. The Clinical Impression of Severity (CI-S)-assessment ranged from +3 ="normal not ill at all" to -3="among the most extremely ill patients ". Change values were calculated for each period, i.e. treatment with IB1001 (change between the baseline period (average for Visit 1 and Visit 2) and end of treatment period (average for Visit 3 and Visit 4)) and post-treatment washout (between end of treatment period (average for Visit 3 and Visit 4) and end of washout period (average for Visit 5 and Visit 6). Then, the mean change in the post-treatment period was subtracted from the mean change in the treatment with IB1001 period.
Outcome measures
| Measure |
Parent Study
n=29 Participants
6-weeks treatment with IB1001administered orally. Patients ≥13 years old received a total daily dose of 4 g/day (administered as 3 doses per day).
Patients 6-12 years old received weight-tiered doses:
* Patients aged 6-12 years weighing 15 to \<25 kg took 2g per day: 1 g in the morning and 1 g in the evening.
* Patients aged 6-12 years weighing 25 to \<35 kg took 3g per day: 1 g in the morning, 1g in the afternoon, and 1 g in the evening.
* Patients aged 6-12 years weighing ≥35 kg took 4 g per day: 2 g in the morning, 1g in the afternoon and 1 g in the evening (as per adults)
IB1001: IB1001 (N-Acetyl-L-Leucine) is a modified amino-acid ester that is orally administered.
After the 6-week treatment period,patients entered a 6-week post-treatment washout period.
|
|---|---|
|
Key Secondary Endpoint: Change in Severity Based on Average CI-S
|
0.09 score on a scale
Standard Deviation 0.71
|
SECONDARY outcome
Timeframe: Baseline to end of treatment with IB1001 (Parent Study 6-weeks treatment); End of treatment with IB1001 to the end of post 6-week treatment washoutPopulation: The Modified Intention to Treat (mITT) analysis set was defined as all patients who receive at least one dose of the study drug and with one video recording during the baseline period (Visit 1 or 2, or both) and treatment period (Visit 3 or Visit 4, or both). The overall mITT comprised 29 participants. Of these, 29 participants had values for the CI-CS analysis in the Treatment with IB1001 period and 27 participants in the Post-Treatment washout period.
The Clinical Impression of Change in Severity assessment will instruct the blinded rater to consider: compared to the first video, how has the severity of their performance on the 9 Hole Peg Test of the Dominant Hand (9HPT-D) or 8 Meter Walk Test (8MWT) changed (improved or worsened) in 6-weeks as observed in the second video? The Clinical Impression of Change in Severity is evaluated on a 7 point Likert scale (+3=significantly improved to -3= significantly worse). CI-CS scores \<0 were reclassified as worsened (-1), CI-CS scores 0 remained classified as not changed (0), and CI-CS scores \>0 were reclassified as improved (+1). When comparing Visit 4 versus Visit 2 and Visit 6 versus Visit 4, CI-CS scores \<0 were reclassified as worsened (-1), CI-CS scores 0 remained classified as not changed (0), and CI-CS scores \>0 were reclassified as improved (+1).
Outcome measures
| Measure |
Parent Study
n=29 Participants
6-weeks treatment with IB1001administered orally. Patients ≥13 years old received a total daily dose of 4 g/day (administered as 3 doses per day).
Patients 6-12 years old received weight-tiered doses:
* Patients aged 6-12 years weighing 15 to \<25 kg took 2g per day: 1 g in the morning and 1 g in the evening.
* Patients aged 6-12 years weighing 25 to \<35 kg took 3g per day: 1 g in the morning, 1g in the afternoon, and 1 g in the evening.
* Patients aged 6-12 years weighing ≥35 kg took 4 g per day: 2 g in the morning, 1g in the afternoon and 1 g in the evening (as per adults)
IB1001: IB1001 (N-Acetyl-L-Leucine) is a modified amino-acid ester that is orally administered.
After the 6-week treatment period,patients entered a 6-week post-treatment washout period.
|
|---|---|
|
Key Secondary Endpoint: CI-CS Score Reclassified on a 3-Point Scale
Treatment with IB1001 · -1 (Worsened)
|
12 Participants
|
|
Key Secondary Endpoint: CI-CS Score Reclassified on a 3-Point Scale
Treatment with IB1001 · 0 (No observable change)
|
1 Participants
|
|
Key Secondary Endpoint: CI-CS Score Reclassified on a 3-Point Scale
Treatment with IB1001 · +1 (Improved)
|
16 Participants
|
|
Key Secondary Endpoint: CI-CS Score Reclassified on a 3-Point Scale
Post-treatment washout · -1 (Worsened)
|
16 Participants
|
|
Key Secondary Endpoint: CI-CS Score Reclassified on a 3-Point Scale
Post-treatment washout · 0 (No observable change)
|
3 Participants
|
|
Key Secondary Endpoint: CI-CS Score Reclassified on a 3-Point Scale
Post-treatment washout · +1 (Improved)
|
8 Participants
|
SECONDARY outcome
Timeframe: CI-CS of the non-primary anchor test was evaluated, comparing the CI-CS of Visit 4 (end of treatment) versus Visit 2 (baseline) and of Visit 6 (end of washout) versus Visit 4 (end of treatment) as done for the primary anchor test.Population: Modified Intention to Treat (mITT) Analysis Set is defined as all patients who receive at least one dose of the study drug and with one video recording during the baseline period (Visit 1 or 2, or both) and treatment period (Visit 3 or Visit 4, or both). The overall mITT comprised 29 participants. Of these, 22 participants had values for the CI-CS Score for the Non-Primary Anchor Test analysis in the Treatment with IB1001 period and 20 participants in the Post-Treatment washout period
The Clinical Impression of Change in Severity assessment will instruct the blinded rater to consider: compared to the first video, how has the severity of their performance on the 9 Hole Peg Test of the Dominant Hand (9HPT-D) or 8 Meter Walk Test (8MWT) changed (improved or worsened) in 6-weeks as observed in the second video? The Clinical Impression of Change in Severity is evaluated on a 7 point Likert scale (+3=significantly improved to -3= significantly worse). Change values were calculated for each period, i.e. treatment with IB1001 (comparing the end of treatment (Visit 4) with baseline (Visit 2)) and post-treatment washout (comparing the end of washout (Visit 6) with the end of treatment (Visit 4)).
Outcome measures
| Measure |
Parent Study
n=29 Participants
6-weeks treatment with IB1001administered orally. Patients ≥13 years old received a total daily dose of 4 g/day (administered as 3 doses per day).
Patients 6-12 years old received weight-tiered doses:
* Patients aged 6-12 years weighing 15 to \<25 kg took 2g per day: 1 g in the morning and 1 g in the evening.
* Patients aged 6-12 years weighing 25 to \<35 kg took 3g per day: 1 g in the morning, 1g in the afternoon, and 1 g in the evening.
* Patients aged 6-12 years weighing ≥35 kg took 4 g per day: 2 g in the morning, 1g in the afternoon and 1 g in the evening (as per adults)
IB1001: IB1001 (N-Acetyl-L-Leucine) is a modified amino-acid ester that is orally administered.
After the 6-week treatment period,patients entered a 6-week post-treatment washout period.
|
|---|---|
|
Key Secondary Endpoint: CI-CS Score for the Non-Primary Anchor Test
Treatment with IB1001
|
-0.30 score on a scale
Standard Deviation 1.33
|
|
Key Secondary Endpoint: CI-CS Score for the Non-Primary Anchor Test
Post-treatment washout
|
0.23 score on a scale
Standard Deviation 1.43
|
SECONDARY outcome
Timeframe: Change values were calculated for each period, i.e. treatment with IB1001 (comparing the end of treatment (Visit 4) with baseline (Visit 2)) and post-treatment washout (comparing the end of washout (Visit 6) with the end of treatment (Visit 4)).Population: Modified Intention to Treat (mITT) Analysis Set is defined as all patients who receive at least one dose of the study drug and with one video recording during the baseline period (Visit 1 or 2, or both) and treatment period (Visit 3 or Visit 4, or both). The overall mITT comprised 29 participants. Of these, 26 participants had values for the SCAFI Total score analysis in the Treatment with IB1001 period and 25 participants in the Post-Treatment washout period
Spinocerebellar Ataxia Functional Index (SCAFI) is composed of 8 Meter Walk Test, 9-Hole Peg Test of Dominant and Non-Dominant Hand (9HPT-D/9HPT-ND) (the 3 tests are timed assessments; each is done twice and values are averaged; the 8MWT and 9HPT-D and 9HPT-ND values are converted from times to rates, and the results expressed as a composite Z-score of each test relative to baseline) and the PATA rate (counted number how often a patient can repeat the syllables "PATA" within 10 seconds), a measure of speech performance. The scores of these 3 were transformed to Z-scores (=individual's average of both trials to perform the respective task -mean of study population at baseline) / SD of study population at baseline). A Z-score of 0 equates to the population mean at baseline. For all 3, higher Z-scores (above mean) mean better performance. The SCAFI total score was calculated as the arithmetic mean of the non-missing Z-scores for the 3. A higher total score means better performance.
Outcome measures
| Measure |
Parent Study
n=29 Participants
6-weeks treatment with IB1001administered orally. Patients ≥13 years old received a total daily dose of 4 g/day (administered as 3 doses per day).
Patients 6-12 years old received weight-tiered doses:
* Patients aged 6-12 years weighing 15 to \<25 kg took 2g per day: 1 g in the morning and 1 g in the evening.
* Patients aged 6-12 years weighing 25 to \<35 kg took 3g per day: 1 g in the morning, 1g in the afternoon, and 1 g in the evening.
* Patients aged 6-12 years weighing ≥35 kg took 4 g per day: 2 g in the morning, 1g in the afternoon and 1 g in the evening (as per adults)
IB1001: IB1001 (N-Acetyl-L-Leucine) is a modified amino-acid ester that is orally administered.
After the 6-week treatment period,patients entered a 6-week post-treatment washout period.
|
|---|---|
|
Spinocerebellar Ataxia Functional Index (SCAFI) [Schmitz-Hübsch et al, 2008]
Treatment with IB1001
|
0.0163 Z-scores
Standard Deviation 0.2749
|
|
Spinocerebellar Ataxia Functional Index (SCAFI) [Schmitz-Hübsch et al, 2008]
Post-treatment washout
|
-0.0080 Z-scores
Standard Deviation 0.2420
|
SECONDARY outcome
Timeframe: Baseline to end of treatment with IB1001 (Parent Study Day 42); End of treatment with IB1001 to the end of post treatment washoutPopulation: The Modified Intention to Treat (mITT) analysis set was defined as all patients who receive at least one dose of the study drug and with one video recording during the baseline period (Visit 1 or 2, or both) and treatment period (Visit 3 or Visit 4, or both). The overall mITT comprised 29 participants. Of these, 28 participants had values for the SARA analysis in the Treatment with IB1001 period and 27 participants in the Post-Treatment washout period.
The Scale for Assessment and Rating of Ataxia has 8 items that are related to gait, stance, sitting, speech, finger-chase test, nose-finger test, fast alternating movements, and heel-shin test. The range is 0-40 points, with a lower score representing neurological improvement and a higher score representing neurological worsening. Change values were calculated for each period, i.e. treatment with IB1001 (comparing the end of treatment (Visit 4) with baseline (Visit 2)) and post-treatment washout (comparing the end of washout (Visit 6) with the end of treatment (Visit 4)).
Outcome measures
| Measure |
Parent Study
n=29 Participants
6-weeks treatment with IB1001administered orally. Patients ≥13 years old received a total daily dose of 4 g/day (administered as 3 doses per day).
Patients 6-12 years old received weight-tiered doses:
* Patients aged 6-12 years weighing 15 to \<25 kg took 2g per day: 1 g in the morning and 1 g in the evening.
* Patients aged 6-12 years weighing 25 to \<35 kg took 3g per day: 1 g in the morning, 1g in the afternoon, and 1 g in the evening.
* Patients aged 6-12 years weighing ≥35 kg took 4 g per day: 2 g in the morning, 1g in the afternoon and 1 g in the evening (as per adults)
IB1001: IB1001 (N-Acetyl-L-Leucine) is a modified amino-acid ester that is orally administered.
After the 6-week treatment period,patients entered a 6-week post-treatment washout period.
|
|---|---|
|
Scale for Assessment and Rating of Ataxia (SARA) Score [Schmitz-Hübsch Etal, 2006; Subramony, 2007]
Treatment with IB1001
|
-1.41 score on a scale
Standard Deviation 1.67
|
|
Scale for Assessment and Rating of Ataxia (SARA) Score [Schmitz-Hübsch Etal, 2006; Subramony, 2007]
Post-treatment washout
|
1.43 score on a scale
Standard Deviation 2.08
|
SECONDARY outcome
Timeframe: Baseline to end of treatment with IB1001 (Parent Study 6-week treatment): observed VAS values at visit 4; End of treatment with IB1001 to the end of post treatment washout: observed VAS values at visit 6.Population: The Modified Intention to Treat (mITT) analysis set was defined as all patients who receive at least one dose of the study drug and with one video recording during the baseline period (Visit 1 or 2, or both) and treatment period (Visit 3 or Visit 4, or both). The overall mITT comprised 29 participants. Of these, 28 participants had values for the EQ-5D VAS analysis in the Treatment with IB1001 period and 27 participants in the Post-Treatment washout period.
For posting, health-related quality of life based on the EQ-5D visual analogue scale (VAS) was presented as a secondary endpoint. EQ-5D VAS is a 0-100 scale where patients are asked to indicate their overall health, with a score of 0 indicating worst health and a score of 100indicating best health.
Outcome measures
| Measure |
Parent Study
n=29 Participants
6-weeks treatment with IB1001administered orally. Patients ≥13 years old received a total daily dose of 4 g/day (administered as 3 doses per day).
Patients 6-12 years old received weight-tiered doses:
* Patients aged 6-12 years weighing 15 to \<25 kg took 2g per day: 1 g in the morning and 1 g in the evening.
* Patients aged 6-12 years weighing 25 to \<35 kg took 3g per day: 1 g in the morning, 1g in the afternoon, and 1 g in the evening.
* Patients aged 6-12 years weighing ≥35 kg took 4 g per day: 2 g in the morning, 1g in the afternoon and 1 g in the evening (as per adults)
IB1001: IB1001 (N-Acetyl-L-Leucine) is a modified amino-acid ester that is orally administered.
After the 6-week treatment period,patients entered a 6-week post-treatment washout period.
|
|---|---|
|
EuroQuol- 5 Dimension (EQ-5D) Quality of Life Scale: Visual Analogue Scale (VAS)
Treatment with IB1001
|
71.3 score on a scale
Standard Deviation 23.2
|
|
EuroQuol- 5 Dimension (EQ-5D) Quality of Life Scale: Visual Analogue Scale (VAS)
Post-Treatment Washout
|
71.1 score on a scale
Standard Deviation 21.2
|
SECONDARY outcome
Timeframe: Baseline to end of treatment with IB1001 (Parent Study 6-weeks treatment); End of treatment with IB1001 to the end of post treatment washout.Population: The Modified Intention to Treat (mITT) analysis set was defined as all patients who receive at least one dose of the study drug and with one video recording during the baseline period (Visit 1 or 2, or both) and treatment period (Visit 3 or Visit 4, or both). The overall mITT comprised 29 participants. Of these, 28 participants had values for the mDRS analysis in the Treatment with IB1001 period and 27 participants in the Post-Treatment washout period
Overall neurological status based on six domains (ambulation, manipulation,language, swallowing, seizures and ocular movements). The Modified Disability Rating Scale (mDRS) ranges from 0-24, where 0 is the best neurological status and 24 is the worst. Change values were calculated for each period, i.e. treatment with IB1001 (comparing the end of treatment (Visit 4) with baseline (Visit 2)) and post-treatment washout (comparing the end of washout (Visit 6) with the end of treatment (Visit 4))
Outcome measures
| Measure |
Parent Study
n=29 Participants
6-weeks treatment with IB1001administered orally. Patients ≥13 years old received a total daily dose of 4 g/day (administered as 3 doses per day).
Patients 6-12 years old received weight-tiered doses:
* Patients aged 6-12 years weighing 15 to \<25 kg took 2g per day: 1 g in the morning and 1 g in the evening.
* Patients aged 6-12 years weighing 25 to \<35 kg took 3g per day: 1 g in the morning, 1g in the afternoon, and 1 g in the evening.
* Patients aged 6-12 years weighing ≥35 kg took 4 g per day: 2 g in the morning, 1g in the afternoon and 1 g in the evening (as per adults)
IB1001: IB1001 (N-Acetyl-L-Leucine) is a modified amino-acid ester that is orally administered.
After the 6-week treatment period,patients entered a 6-week post-treatment washout period.
|
|---|---|
|
Modified Disability Rating Scale (mDRS) [Iturriaga et al. 2006]
Treatment with IB1001
|
-0.030 score on a scale
Standard Deviation 0.075
|
|
Modified Disability Rating Scale (mDRS) [Iturriaga et al. 2006]
Post-Treatment Washout
|
0.042 score on a scale
Standard Deviation 0.058
|
SECONDARY outcome
Timeframe: Baseline to end of treatment with IB1001 (Parent Study 6-weeks treatment); End of treatment with IB1001 to the end of post treatment washout.Population: The Modified Intention to Treat (mITT) analysis set was defined as all patients who receive at least one dose of the study drug and with one video recording during the baseline period (Visit 1 or 2, or both) and treatment period (Visit 3 or Visit 4, or both). The overall mITT comprised 29 participants. Of these, 28 participants had values for theInvestigator's CGI-C analysis in the Treatment with IB1001 period and 27 participants in the Post-Treatment washout period.
The Clinical Global Impression of Change assessed by the investigator is evaluated on a 7 point Likert scale ranging from 1='very much improved' to 7='very much worse' Change values were calculated for each period, i.e. treatment with IB1001 (comparing the end of treatment (Visit 4) with baseline (Visit 2)) and post-treatment washout (comparing the end of washout (Visit 6) with the end of treatment (Visit 4)).
Outcome measures
| Measure |
Parent Study
n=29 Participants
6-weeks treatment with IB1001administered orally. Patients ≥13 years old received a total daily dose of 4 g/day (administered as 3 doses per day).
Patients 6-12 years old received weight-tiered doses:
* Patients aged 6-12 years weighing 15 to \<25 kg took 2g per day: 1 g in the morning and 1 g in the evening.
* Patients aged 6-12 years weighing 25 to \<35 kg took 3g per day: 1 g in the morning, 1g in the afternoon, and 1 g in the evening.
* Patients aged 6-12 years weighing ≥35 kg took 4 g per day: 2 g in the morning, 1g in the afternoon and 1 g in the evening (as per adults)
IB1001: IB1001 (N-Acetyl-L-Leucine) is a modified amino-acid ester that is orally administered.
After the 6-week treatment period,patients entered a 6-week post-treatment washout period.
|
|---|---|
|
Investigator's Clinical Global Impressions of Change (CGI-c)
Treatment with IB1001
|
3.2 score on a scale
Standard Deviation 1.0
|
|
Investigator's Clinical Global Impressions of Change (CGI-c)
Post-Treatment Washout
|
4.9 score on a scale
Standard Deviation 0.8
|
SECONDARY outcome
Timeframe: Baseline to end of treatment with IB1001 (Parent Study 6-week treatment); End of treatment with IB1001 to the end of post treatment washoutPopulation: The Modified Intention to Treat (mITT) analysis set was defined as all patients who receive at least one dose of the study drug and with one video recording during the baseline period (Visit 1 or 2, or both) and treatment period (Visit 3 or Visit 4, or both). The overall mITT comprised 29 participants. Of these, 26 participants had values for the Parent/Caregiver's CGI-C analysis in the Treatment with IB1001 period and 25 participants in the Post-Treatment washout period.
The Clinical Global Impression of Change assessed by the parent/caregiver is evaluated on a 7 point Likert scale ranging from 1='very much improved' to 7='very much worse'. Change values were calculated for each period, i.e. treatment with IB1001 (comparing the end of treatment (Visit 4) with baseline (Visit 2)) and post-treatment washout (comparing the end of washout (Visit 6) with the end of treatment (Visit 4)).
Outcome measures
| Measure |
Parent Study
n=29 Participants
6-weeks treatment with IB1001administered orally. Patients ≥13 years old received a total daily dose of 4 g/day (administered as 3 doses per day).
Patients 6-12 years old received weight-tiered doses:
* Patients aged 6-12 years weighing 15 to \<25 kg took 2g per day: 1 g in the morning and 1 g in the evening.
* Patients aged 6-12 years weighing 25 to \<35 kg took 3g per day: 1 g in the morning, 1g in the afternoon, and 1 g in the evening.
* Patients aged 6-12 years weighing ≥35 kg took 4 g per day: 2 g in the morning, 1g in the afternoon and 1 g in the evening (as per adults)
IB1001: IB1001 (N-Acetyl-L-Leucine) is a modified amino-acid ester that is orally administered.
After the 6-week treatment period,patients entered a 6-week post-treatment washout period.
|
|---|---|
|
Parent/Caregiver's Clinical Global Impression of Change (CGI-C)
Treatment With IB1001
|
3.2 score on a scale
Standard Deviation 1.2
|
|
Parent/Caregiver's Clinical Global Impression of Change (CGI-C)
Post-Treatment Washout
|
4.8 score on a scale
Standard Deviation 1.0
|
SECONDARY outcome
Timeframe: Baseline to end of treatment with IB1001 (Parent Study 6-weeks treatment); End of treatment with IB1001 to the end of post treatment washout.Population: The Modified Intention to Treat (mITT) analysis set was defined as all patients who receive at least one dose of the study drug and with one video recording during the baseline period (Visit 1 or 2, or both) and treatment period (Visit 3 or Visit 4, or both). The overall mITT comprised 29 participants. Of these, 28 participants had values for the Patient's CGI if Able analysis in the Treatment with IB1001 period and 27 participants in the Post-Treatment washout period.
The Clinical Global Impression of Change assessed by the patient (if able) is evaluated on a 7 point Likert scale ranging from 1='very much improved' to 7='very much worse'. Change values were calculated for each period, i.e. treatment with IB1001 (comparing the end of treatment (Visit 4) with baseline (Visit 2)) and post-treatment washout (comparing the end of washout (Visit 6) with the end of treatment (Visit 4)).
Outcome measures
| Measure |
Parent Study
n=29 Participants
6-weeks treatment with IB1001administered orally. Patients ≥13 years old received a total daily dose of 4 g/day (administered as 3 doses per day).
Patients 6-12 years old received weight-tiered doses:
* Patients aged 6-12 years weighing 15 to \<25 kg took 2g per day: 1 g in the morning and 1 g in the evening.
* Patients aged 6-12 years weighing 25 to \<35 kg took 3g per day: 1 g in the morning, 1g in the afternoon, and 1 g in the evening.
* Patients aged 6-12 years weighing ≥35 kg took 4 g per day: 2 g in the morning, 1g in the afternoon and 1 g in the evening (as per adults)
IB1001: IB1001 (N-Acetyl-L-Leucine) is a modified amino-acid ester that is orally administered.
After the 6-week treatment period,patients entered a 6-week post-treatment washout period.
|
|---|---|
|
Patient's Clinical Global Impressions (CGI) if Able
Treatment With IB1001
|
3.0 score on a scale
Standard Deviation 1.1
|
|
Patient's Clinical Global Impressions (CGI) if Able
Post-Treatment Washout
|
4.6 score on a scale
Standard Deviation 1.2
|
Adverse Events
Treatment With IB1001
Post-Treatment Washout
Serious adverse events
| Measure |
Treatment With IB1001
n=30 participants at risk
Parent Study: 6-weeks treatment with IB1001 administered orally. Patients ≥13 years old in Europe and ≥18 years old in the United States received a total daily dose of 4 g/day (administered as 3 doses per day).
Patients 6-12 years old received weight-tiered doses:
* Patients aged 6-12 years weighing 15 to \<25 kg took 2 g per day: 1g in the morning and 1 g in the evening.
* Patients aged 6-12 years weighing 25 to \<35 kg took 3 g per day: 1g in the morning, 1 g in the afternoon, and 1 g in the evening.
* Patients aged 6-12 years weighing ≥35 kg took 4 g per day: 2g in the morning, 1 g in the afternoon and 1g in the evening (as per adults)
IB1001: IB1001 (N-Acetyl-L-Leucine) is a modified amino-acid ester that is orally administered.
|
Post-Treatment Washout
n=30 participants at risk
After the Parent Study 6-week treatment period, patients entered a 6-week post-treatment washout period.
|
|---|---|---|
|
Injury, poisoning and procedural complications
Fall
|
3.3%
1/30 • Number of events 1 • From signing of the informed consent form through to End of Study (Day 84, scheduled at 42 days post last IB1001dose).
Adverse events (AEs) / serious adverse events (SAEs) consistent with the definition from ClinicalTrial.Gov. AEs/SAEs were collected in accordance with International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use - Good Clinical Practice (ICH-CGP).
|
0.00%
0/30 • From signing of the informed consent form through to End of Study (Day 84, scheduled at 42 days post last IB1001dose).
Adverse events (AEs) / serious adverse events (SAEs) consistent with the definition from ClinicalTrial.Gov. AEs/SAEs were collected in accordance with International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use - Good Clinical Practice (ICH-CGP).
|
|
Injury, poisoning and procedural complications
Lumbar vertebral fracture
|
3.3%
1/30 • Number of events 1 • From signing of the informed consent form through to End of Study (Day 84, scheduled at 42 days post last IB1001dose).
Adverse events (AEs) / serious adverse events (SAEs) consistent with the definition from ClinicalTrial.Gov. AEs/SAEs were collected in accordance with International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use - Good Clinical Practice (ICH-CGP).
|
0.00%
0/30 • From signing of the informed consent form through to End of Study (Day 84, scheduled at 42 days post last IB1001dose).
Adverse events (AEs) / serious adverse events (SAEs) consistent with the definition from ClinicalTrial.Gov. AEs/SAEs were collected in accordance with International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use - Good Clinical Practice (ICH-CGP).
|
|
Psychiatric disorders
Psychotic disorder
|
3.3%
1/30 • Number of events 1 • From signing of the informed consent form through to End of Study (Day 84, scheduled at 42 days post last IB1001dose).
Adverse events (AEs) / serious adverse events (SAEs) consistent with the definition from ClinicalTrial.Gov. AEs/SAEs were collected in accordance with International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use - Good Clinical Practice (ICH-CGP).
|
0.00%
0/30 • From signing of the informed consent form through to End of Study (Day 84, scheduled at 42 days post last IB1001dose).
Adverse events (AEs) / serious adverse events (SAEs) consistent with the definition from ClinicalTrial.Gov. AEs/SAEs were collected in accordance with International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use - Good Clinical Practice (ICH-CGP).
|
|
Psychiatric disorders
Bipolar disorder
|
3.3%
1/30 • Number of events 1 • From signing of the informed consent form through to End of Study (Day 84, scheduled at 42 days post last IB1001dose).
Adverse events (AEs) / serious adverse events (SAEs) consistent with the definition from ClinicalTrial.Gov. AEs/SAEs were collected in accordance with International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use - Good Clinical Practice (ICH-CGP).
|
0.00%
0/30 • From signing of the informed consent form through to End of Study (Day 84, scheduled at 42 days post last IB1001dose).
Adverse events (AEs) / serious adverse events (SAEs) consistent with the definition from ClinicalTrial.Gov. AEs/SAEs were collected in accordance with International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use - Good Clinical Practice (ICH-CGP).
|
Other adverse events
| Measure |
Treatment With IB1001
n=30 participants at risk
Parent Study: 6-weeks treatment with IB1001 administered orally. Patients ≥13 years old in Europe and ≥18 years old in the United States received a total daily dose of 4 g/day (administered as 3 doses per day).
Patients 6-12 years old received weight-tiered doses:
* Patients aged 6-12 years weighing 15 to \<25 kg took 2 g per day: 1g in the morning and 1 g in the evening.
* Patients aged 6-12 years weighing 25 to \<35 kg took 3 g per day: 1g in the morning, 1 g in the afternoon, and 1 g in the evening.
* Patients aged 6-12 years weighing ≥35 kg took 4 g per day: 2g in the morning, 1 g in the afternoon and 1g in the evening (as per adults)
IB1001: IB1001 (N-Acetyl-L-Leucine) is a modified amino-acid ester that is orally administered.
|
Post-Treatment Washout
n=30 participants at risk
After the Parent Study 6-week treatment period, patients entered a 6-week post-treatment washout period.
|
|---|---|---|
|
Injury, poisoning and procedural complications
Fall
|
23.3%
7/30 • Number of events 10 • From signing of the informed consent form through to End of Study (Day 84, scheduled at 42 days post last IB1001dose).
Adverse events (AEs) / serious adverse events (SAEs) consistent with the definition from ClinicalTrial.Gov. AEs/SAEs were collected in accordance with International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use - Good Clinical Practice (ICH-CGP).
|
20.0%
6/30 • Number of events 7 • From signing of the informed consent form through to End of Study (Day 84, scheduled at 42 days post last IB1001dose).
Adverse events (AEs) / serious adverse events (SAEs) consistent with the definition from ClinicalTrial.Gov. AEs/SAEs were collected in accordance with International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use - Good Clinical Practice (ICH-CGP).
|
|
Injury, poisoning and procedural complications
Contusion
|
0.00%
0/30 • From signing of the informed consent form through to End of Study (Day 84, scheduled at 42 days post last IB1001dose).
Adverse events (AEs) / serious adverse events (SAEs) consistent with the definition from ClinicalTrial.Gov. AEs/SAEs were collected in accordance with International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use - Good Clinical Practice (ICH-CGP).
|
10.0%
3/30 • Number of events 4 • From signing of the informed consent form through to End of Study (Day 84, scheduled at 42 days post last IB1001dose).
Adverse events (AEs) / serious adverse events (SAEs) consistent with the definition from ClinicalTrial.Gov. AEs/SAEs were collected in accordance with International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use - Good Clinical Practice (ICH-CGP).
|
|
Nervous system disorders
Tremor
|
13.3%
4/30 • Number of events 4 • From signing of the informed consent form through to End of Study (Day 84, scheduled at 42 days post last IB1001dose).
Adverse events (AEs) / serious adverse events (SAEs) consistent with the definition from ClinicalTrial.Gov. AEs/SAEs were collected in accordance with International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use - Good Clinical Practice (ICH-CGP).
|
3.3%
1/30 • Number of events 1 • From signing of the informed consent form through to End of Study (Day 84, scheduled at 42 days post last IB1001dose).
Adverse events (AEs) / serious adverse events (SAEs) consistent with the definition from ClinicalTrial.Gov. AEs/SAEs were collected in accordance with International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use - Good Clinical Practice (ICH-CGP).
|
|
Nervous system disorders
Balance disorder
|
6.7%
2/30 • Number of events 2 • From signing of the informed consent form through to End of Study (Day 84, scheduled at 42 days post last IB1001dose).
Adverse events (AEs) / serious adverse events (SAEs) consistent with the definition from ClinicalTrial.Gov. AEs/SAEs were collected in accordance with International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use - Good Clinical Practice (ICH-CGP).
|
3.3%
1/30 • Number of events 1 • From signing of the informed consent form through to End of Study (Day 84, scheduled at 42 days post last IB1001dose).
Adverse events (AEs) / serious adverse events (SAEs) consistent with the definition from ClinicalTrial.Gov. AEs/SAEs were collected in accordance with International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use - Good Clinical Practice (ICH-CGP).
|
|
Nervous system disorders
Seizure
|
0.00%
0/30 • From signing of the informed consent form through to End of Study (Day 84, scheduled at 42 days post last IB1001dose).
Adverse events (AEs) / serious adverse events (SAEs) consistent with the definition from ClinicalTrial.Gov. AEs/SAEs were collected in accordance with International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use - Good Clinical Practice (ICH-CGP).
|
6.7%
2/30 • Number of events 2 • From signing of the informed consent form through to End of Study (Day 84, scheduled at 42 days post last IB1001dose).
Adverse events (AEs) / serious adverse events (SAEs) consistent with the definition from ClinicalTrial.Gov. AEs/SAEs were collected in accordance with International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use - Good Clinical Practice (ICH-CGP).
|
|
General disorders
Fatigue
|
6.7%
2/30 • Number of events 2 • From signing of the informed consent form through to End of Study (Day 84, scheduled at 42 days post last IB1001dose).
Adverse events (AEs) / serious adverse events (SAEs) consistent with the definition from ClinicalTrial.Gov. AEs/SAEs were collected in accordance with International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use - Good Clinical Practice (ICH-CGP).
|
0.00%
0/30 • From signing of the informed consent form through to End of Study (Day 84, scheduled at 42 days post last IB1001dose).
Adverse events (AEs) / serious adverse events (SAEs) consistent with the definition from ClinicalTrial.Gov. AEs/SAEs were collected in accordance with International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use - Good Clinical Practice (ICH-CGP).
|
|
Renal and urinary disorders
Incontinence
|
0.00%
0/30 • From signing of the informed consent form through to End of Study (Day 84, scheduled at 42 days post last IB1001dose).
Adverse events (AEs) / serious adverse events (SAEs) consistent with the definition from ClinicalTrial.Gov. AEs/SAEs were collected in accordance with International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use - Good Clinical Practice (ICH-CGP).
|
6.7%
2/30 • Number of events 2 • From signing of the informed consent form through to End of Study (Day 84, scheduled at 42 days post last IB1001dose).
Adverse events (AEs) / serious adverse events (SAEs) consistent with the definition from ClinicalTrial.Gov. AEs/SAEs were collected in accordance with International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use - Good Clinical Practice (ICH-CGP).
|
|
Musculoskeletal and connective tissue disorders
Arthralgia
|
6.7%
2/30 • Number of events 2 • From signing of the informed consent form through to End of Study (Day 84, scheduled at 42 days post last IB1001dose).
Adverse events (AEs) / serious adverse events (SAEs) consistent with the definition from ClinicalTrial.Gov. AEs/SAEs were collected in accordance with International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use - Good Clinical Practice (ICH-CGP).
|
0.00%
0/30 • From signing of the informed consent form through to End of Study (Day 84, scheduled at 42 days post last IB1001dose).
Adverse events (AEs) / serious adverse events (SAEs) consistent with the definition from ClinicalTrial.Gov. AEs/SAEs were collected in accordance with International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use - Good Clinical Practice (ICH-CGP).
|
|
Infections and infestations
Respiratory tract infection
|
6.7%
2/30 • Number of events 2 • From signing of the informed consent form through to End of Study (Day 84, scheduled at 42 days post last IB1001dose).
Adverse events (AEs) / serious adverse events (SAEs) consistent with the definition from ClinicalTrial.Gov. AEs/SAEs were collected in accordance with International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use - Good Clinical Practice (ICH-CGP).
|
0.00%
0/30 • From signing of the informed consent form through to End of Study (Day 84, scheduled at 42 days post last IB1001dose).
Adverse events (AEs) / serious adverse events (SAEs) consistent with the definition from ClinicalTrial.Gov. AEs/SAEs were collected in accordance with International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use - Good Clinical Practice (ICH-CGP).
|
Additional Information
Taylor Fields, Chief Product Development Officer
IntraBio Ltd.
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place